Kumar Shah, MD
Critical Care Medicine · Buffalo, NYNPI 1538351986
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,847, more than ten times the $278 reported in 2019. Among critical care medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 156 payments — averaging $30.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$971
- Regeneron Healthcare Solutions, Inc.$316
- Actelion Pharmaceuticals US, Inc.$291
- Abiomed$278
- Viatris Specialty LLC$278
- plus $2K from 18 others
What the payments were for
- Travel & lodging$2395%
- Food & beverage$4,52495%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $1,041 |
| GSK | 45 | $971 |
| Regeneron Healthcare Solutions, Inc. | 6 | $316 |
| Actelion Pharmaceuticals US, Inc. | 3 | $291 |
| Abiomed | 2 | $278 |
| Viatris Specialty LLC | 8 | $278 |
| Boehringer Ingelheim | 7 | $263 |
| Verona Pharma, Inc. | 7 | $263 |
| Sanofi | 7 | $183 |
| Imperative Care, Inc | 1 | $150 |
| Amgen | 7 | $142 |
| Grifols USA, LLC | 7 | $138 |
| Inogen, Inc. | 5 | $99 |
| Insmed, Inc. | 3 | $67 |
| Mylan Specialty L.p. | 4 | $58 |
| Electromed, Inc. | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Baxter Healthcare | 1 | $29 |
| Pentax Of America, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| Covis Pharma GmbH | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,763 in reported general payments places this provider in the 90th percentile of 442 critical care medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 20 | $260,646 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 234 | $193,904 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 76 | $56,868 |
| Breo ElliptaFluticasone/Vilanterol | 70 | $34,476 |
| Spiriva RespimatTiotropium Bromide | 24 | $18,340 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 65 | $12,079 |
| Spiriva HandihalerTiotropium Bromide | 15 | $11,378 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $7,018 |
| Arnuity ElliptaFluticasone Furoate | 30 | $6,993 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $5,575 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 148 | $5,246 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,386 |
| Striverdi RespimatOlodaterol Hcl | 11 | $2,816 |
| Roflumilast | 12 | $1,529 |
| Montelukast Sodium | 112 | $1,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Striverdi Respimat | $263 | $281,80255 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $971 | $242,391350 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,041 | $61,25492 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 442 critical care medicine providers in New York.
Other critical care medicine in Buffalo
- Marwan SaoudBuffalo$7K
- Joshua RosenbergBrooklyn$881K
- Peter DicpinigaitisBronx$241K
- Roxana SulicaNew York$211K
- Boris ShkolnikAlbany$209K
- Paul StrachanMelville$169K
- Anna PodolanczukNew York$116K
- Joanne HessneyRochester$76K
- Jan BakkerNew York$49K
- Hugh CassiereManhasset$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.